Lifeward ($LFWD): Can ReWalk and AlterG Turn Sales Growth into Cash?

01 Scenarios: sales recovery, financing and the cost per share

Bull case

The favorable scenario requires the device recovery to continue, collections to improve and operating cash consumption to fall before further financing overwhelms the benefit per share. Second-quarter 2026 revenue rose approximately 16% from a year earlier, led by AlterG and ReWalk, but that is a starting point rather than proof of a self-financing business. The October 30 proposal could remove an issuance constraint; the favorable interpretation also requires the resulting capital flexibility to produce useful operating progress. Source Source

Commercial execution would be more persuasive if expanding sales came with stronger gross profit and less cash tied up in receivables. New distribution relationships could help reach patients and clinics, while the September product roadmap provides longer-term opportunities. Those opportunities need actual purchases, regulatory clearance where applicable and funding. An optimistic outcome does not require treating every announced product as already commercial or every conditional financing tranche as money in the bank. Source Source

Base case

The central scenario is a company that sells established rehabilitation products but continues to depend on external capital while building a broader portfolio. First-half 2026 revenue of $10.546 million remained below the previous year’s $10.758 million despite the stronger second quarter. Cash of $9.448 million at June 30 included most of the proceeds associated with the July financing, so the headline closing amount cannot simply be added again. The business has more resources than at year-end, yet the August quarterly report still identifies substantial doubt about its ability to continue as a going concern. Source

Under this interpretation, the vote, the next financial report and the management handover matter sooner than distant product launches. Progress is possible without an immediate cash-flow turnaround. The key question is whether successive financings purchase enough operating improvement to compensate for the expanding share base and debt obligations.

Bear case

The adverse scenario is that revenue growth fails to translate into collections and gross profit, forcing more financing while conversion and warrant exposure remain large. At June 30, 2026, receivables were $7.861 million and purchase commitments due within a year were $10.696 million. These are different balance-sheet and contractual exposures, but both make working-capital discipline important. A slower reimbursement cycle or inventory build can absorb cash even when reported sales improve. Source

The September 25 proxy illustrates the scale of dilution: the initial July notes and related warrants alone cover 2,066,662 shares before interest, compared with 2,832,016 ordinary shares outstanding at September 23. That is potential issuance, not a claim that all those shares have already entered the market. If operations require repeated financing, however, the distinction between a successful company transaction and a favorable result for existing shareholders becomes decisive. Source

What Would Falsify This Reading

The financing-sensitive recovery thesis should change when operating cash conversion or actual issuance changes, rather than simply when a new product is announced.

• A stronger cash result. Sustained collections and materially lower operating cash consumption would weaken the interpretation of persistent financing dependence. The baseline is $9.680 million of H1 2026 operating outflow. Source
• Weaker commercial economics. Continued sales growth with lower gross margin and expanding receivables would undermine the constructive case. The June-quarter baseline is 40.9% gross margin and June receivables of $7.861 million. Source
• A different capital outcome. The October 30 vote and subsequent conversion, exercise or funding outcomes could change the share and debt picture. A proposal or registered resale is not the completed event. Source Source
• New clinical evidence. Prospective oral-insulin results could change the development assessment; the September plan and historical subgroup rationale are not new clinical success. Source Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 The calendar: October 30 comes before the distant product roadmap

The next fixed corporate catalyst is the annual meeting scheduled for October 30, 2026, at 10 a.m. Israel time. Proposal 5 seeks shareholder approval for ordinary shares issued on conversion of specified notes and exercise of warrants, including issuance above the Nasdaq exchange cap. A passed resolution would remove that cap for the covered securities; it would not itself mean every note converts, every warrant is exercised or new cash arrives immediately. A failed vote would leave the issuance restriction and related closing limitations in place. Source

The voting result therefore needs to be read with the terms of the financing, not as a standalone positive or negative headline. Removing the restriction improves flexibility while expanding the ability to issue shares. Keeping it does not erase the debt. The practical follow-up is the actual number of shares issued, the principal remaining outstanding and any cash received from warrant exercise, each reported separately.

The October 1, 2026 filing also creates a near-term management checkpoint. Josh Hexter, already interim chief executive, became interim principal financial and accounting officer after Almog Adar’s departure took effect on September 30. The previously announced November 1 CFO handover to Rami Aviram will not happen: an 8-K filed October 8, 2026 says Aviram informed the company on October 4 that he has decided not to join and will not assume the CFO role. Hexter therefore keeps both the interim chief executive role and the interim principal financial and accounting officer role, without additional compensation, until a successor is appointed, and the company is searching for a permanent CFO. The filing gives no reason. With the October 30 financing vote and the next quarterly report ahead, the finance function remains concentrated in one interim executive. Form 8-K, October 8, 2026 Source Source

The September 8 presentation places AlterG StrideSense in 2027, the upper-body exoskeleton’s planned U.S. and European commercialization in March and September 2028 respectively, ReWalk X in early 2029 and ReBoot in 2030–2031. These are company development targets, subject to execution and required clearances. They offer context for longer-term spending; they do not solve the immediate working-capital question. The oral-insulin program also needs fresh clinical evidence before a development plan becomes a credible commercial asset. Source

03 What the operating business actually sells

Reimbursement is a separate part of the commercial model. Lifeward’s September 2026 SEC-filed presentation identifies HCPCS code K1007, established in 2020, the 2024 Medicare brace-benefit pathway, Medicare Advantage approvals beginning in 2025 and a Veterans Affairs standard operating procedure dating to 2015. It lists a 2026 Medicare fee-schedule rate of $95,081 and estimates coverage access for about 46% of Medicare Advantage enrollees. That is the company’s access estimate, not a count of patients eligible for or guaranteed a device. Its February 17, 2026 release reports Aetna’s prior authorization for one qualifying beneficiary, joining prior authorizations from Humana and UnitedHealthcare; medical-necessity criteria still apply. The September presentation also describes a shift toward HME/DME channel partners handling billing and claims, with wholesale business-to-business terms intended to accelerate collections and reduce operating costs. VA sales remain a direct federal channel. Reimbursement access and the proposed distribution model do not by themselves establish realized sales, margins or cash conversion. SEC filing, Exhibit 99.1; Lifeward press release: ReWalk Personal Exoskeleton now covered by Aetna.

Lifeward’s current commercial base is rehabilitation equipment. ReWalk is a powered exoskeleton for eligible people with spinal cord injury, while AlterG uses body-weight support in treadmills used by rehabilitation and performance facilities. MyoCycle adds a smaller distribution business. The devices address different customers and purchasing decisions, so growth in one product family should not automatically be extrapolated across the portfolio. The June 2026 report describes ReStore as no longer actively commercialized, which makes it inappropriate to count that legacy product as a current expansion engine. Source

For ReWalk, commercial conversion includes patient eligibility, training, reimbursement and delivery. Regulatory clearance permits marketing for the authorized use; it does not guarantee that every potential patient can use the device or obtain coverage. ReWalk 7 received FDA clearance in March 2025, an achieved milestone. The subsequent test is deployment through the relevant care and reimbursement channels, rather than another hypothetical initial approval. Source Source

AlterG sells equipment into clinics and other facilities, with service and related revenue extending beyond the initial device sale. Customer budgets, financing and the availability of components can affect shipment timing. Lifeward attributes the weak start to 2026 partly to working-capital constraints that delayed component purchases and AlterG deliveries. That makes the second-quarter recovery partly a test of whether financing can unblock a functioning sales operation, not simply a measure of new demand. Source

The August 5, 2026 Ottobock Care pilot described in the quarterly report offers access to an organization with more than 50 clinics. A partner’s clinic footprint is not a count of new paying Lifeward customers. The useful evidence will be actual placements, reimbursed patients or orders that flow through the relationship. Similarly, distribution arrangements improve access but need shipment and collection data before they can be treated as durable revenue. Source

04 The second-quarter rebound and the remaining margin problem

For the quarter ended June 30, 2026, revenue increased to $6.623 million from $5.724 million a year earlier, approximately 15.7% calculated growth. Subtracting second-quarter revenue from first-half revenue gives $3.923 million for the first quarter, so the sequential increase was approximately 68.8%. The size of that rebound matters, but its weak comparison quarter also matters. The full first half was still approximately 2.0% below the comparable 2025 period. Source

ReWalk contributed approximately $2.5 million and AlterG approximately $4.1 million of second-quarter 2026 sales, according to the company’s rounded product discussion. ReWalk benefited particularly from Europe, while AlterG benefited from U.S. shipments, service and pricing. The rounded product numbers do not support a more precise total than the reported consolidated revenue. Their value is in identifying what drove the quarter. Source

Gross profit was $2.709 million for the second quarter of 2026, a 40.9% gross margin versus 43.9% a year earlier. Tariffs, currency effects and costs associated with ReWalk revenue sharing and extended warranty coverage weighed on the margin. Faster growth at a lower margin can still increase gross profit, but it leaves less of each sales dollar available for research, selling expenses and administration. Source

Second-quarter operating expenses were $6.861 million and the operating loss was $4.152 million. The apparent expense reduction against the prior year’s $9.074 million includes the disappearance of a $2.783 million impairment charge recorded in 2025. It should not all be interpreted as recurring cash savings. The next report needs to show whether underlying expenses and gross profit are moving toward a smaller operating deficit, rather than merely benefiting from an easier accounting comparison. Source

The operating model also carries a ReWalk revenue-sharing obligation to Oramed. The June 2026 report records $97,000 of second-quarter expense under that arrangement, alongside the underlying 4% revenue-sharing rate described in the annual report. This is a continuing economic cost relevant to the margin earned on growth, distinct from interest on the financing and from the ownership stake held by Oramed. Source Source

The second-quarter 2026 net loss of $11.519 million is not the same as cash burn. Financial expense included $6.912 million of non-cash warrant and derivative valuation changes. Such remeasurement can make the reported loss highly volatile without an equivalent cash payment in the quarter. The financing instruments still have economic consequences, but those consequences are assessed through conversion, interest and settlement terms rather than by treating every fair-value charge as cash spent. Source

Measure the gap in gross profit, not just sales

The Q2 gross profit covered approximately 39.5% of operating expenses, calculated as $2.709 million divided by $6.861 million. That leaves a $4.152 million operating gap before financing items and tax. To close that gap through revenue alone at a constant 40.9% margin would require roughly $10.15 million of additional quarterly sales, bringing the total to approximately $16.78 million. This is about 2.53 times the reported quarter. It is an illustrative accounting calculation, not a sales target, a management forecast or a cash break-even estimate. Inputs

A smaller growth step illustrates the distance still to travel. If quarterly revenue rose by an assumed 25% from $6.623 million, incremental sales would be about $1.656 million. At a constant 40.9% gross margin and unchanged operating expenses, that would add approximately $0.677 million of gross profit and reduce the $4.152 million operating gap to about $3.475 million. This deliberately static scenario excludes mix changes, new hiring, development spending and working-capital effects; it is not a forecast of sales or cash use.

The simplifying assumptions are deliberately visible: margin stays fixed, operating expenses do not rise with volume, and the sales mix does not change. Real expansion could require more selling activity, service capacity, working capital and product support. Conversely, better prices, product mix or cost control could reduce the revenue needed to cover expenses. The calculation shows the scale of the current gap; it does not claim that growth can occur without additional costs or that this exact sales level is achievable.

Margin changes have measurable consequences even before considering more sales. At the same $6.623 million quarterly revenue, each percentage point of gross margin is approximately $66,230 of gross profit. Recovering three percentage points would add about $198,690, all else equal. That is useful improvement, but it would close less than 5% of the $4.152 million operating deficit by itself. A credible turnaround therefore needs several contributions: more profitable deliveries, stronger margin, cost discipline and less cash trapped between shipment and collection.

The comparison with the previous year also benefits from separating one-time charges. Subtracting the prior-year $2.783 million impairment from $9.074 million of operating expenses gives $6.291 million. Against that adjusted comparison, the current $6.861 million is approximately $570,000 higher, or 9.1%. This limited adjustment is not a company-defined non-GAAP measure and does not remove every noncash or unusual item. It explains why the decline in reported total expense does not establish that the recurring operating structure became cheaper. The operating recovery must earn its way through the income statement rather than relying on the disappearance of an old impairment. Expense comparison

05 Cash, burn and an honest runway calculation

At June 30, 2026, Lifeward held $9.448 million in cash and equivalents. Restricted cash of $0.440 million is separate and is not part of freely available liquidity. Cash at December 31, 2025 was $2.169 million, but the subsequent increase was financed by transactions and acquired cash rather than positive operating cash flow. Source

Operations used $9.680 million during the first six months of 2026, compared with $9.429 million a year earlier. Dividing the first-half outflow by six gives a historical average operating burn of approximately $1.613 million per month. Dividing June unrestricted cash by that average gives approximately 5.9 months. This is a static calculation anchored to June 30, not an October cash estimate or a forecast of the date on which the company runs out of money. Source

The July financing needs careful treatment. Approximately $4.1 million of the eventual proceeds had already been received before June 30 and were included in that cash balance. Only approximately $1.5 million remained to arrive in July. The September presentation’s approximately $10.9 million pro forma liquidity incorporates that remaining amount; adding the full $5.58 million financing to June cash would count the earlier receipts twice. Pro forma cash is also not a measurement of the cash remaining after subsequent operating expenditure. Source Source Source

The August 14 quarterly report states that available resources were insufficient to support the operating plan for the following twelve months and identifies substantial doubt about going concern. That judgment remains more informative than mechanically extending a historical burn rate through a period containing acquisitions, financing and changing sales. Reducing burn, collecting receivables and securing capital are all relevant routes to a stronger position; none is established merely by a higher quarter-end cash number. Source

The source of the cash increase makes the point clear. First-half 2026 investing cash flow included $6.500 million acquired with Oratech, while financing activities provided $10.505 million. Those inflows offset operating consumption. They improve the ability to keep operating, but they do not demonstrate that the rehabilitation business has reached cash break-even. Source

06 Collections and commitments: where sales can absorb cash

Trade receivables reached $7.861 million at June 30, 2026, up from $6.138 million at year-end. The $1.723 million increase consumed cash during the first half. A single customer represented 51% of receivables at June 30 and 14.1% of first-half revenue. Those figures identify collection concentration; they do not establish that the customer will fail to pay. They do make the timing of receipts unusually important to a company with limited liquidity. Source

Inventory stood at $6.151 million at June 30, 2026. Lifeward also disclosed $10.696 million of purchase commitments due within a year, principally linked to its expected production needs. A purchase commitment is not the same as outstanding financial debt and is not part of the historic cash burn. It does indicate that ordering components ahead of revenue can consume resources before customers pay. Source

The practical operating test is therefore a sequence: secure parts, ship equipment, recognize sales and collect cash. Disruption at any stage can create a mismatch between encouraging commercial language and available liquidity. The first-quarter component constraints show why the funding question and the sales question cannot be assessed independently. Financing can help fulfill demand, while delayed collections can force the company back to financing even after a good sales quarter. Source

Gross-margin progress would provide additional protection. If tariffs, warranty expense or revenue-sharing costs absorb the benefit of higher shipments, the company must sell more simply to cover the same fixed operating costs. The useful next-quarter comparison combines revenue, gross profit, receivables and cash consumption. A single growth percentage is insufficient to establish the direction of the operating turnaround.

Distinguish a collection benefit from new profit

Applying the disclosed 51% concentration to $7.861 million of receivables gives roughly $4.01 million associated with the largest customer at June 30. That calculation uses a rounded percentage, so it is an approximate exposure rather than an exact customer balance. The amount is equivalent to about two and a half months of the historical H1 operating-use average. It shows why collection timing matters, but says nothing by itself about whether the customer is late, disputes an invoice or will ultimately pay. The filing does not justify assuming a default from concentration alone. Receivables disclosure

A hypothetical $2 million receipt against existing receivables would transfer value from a receivable into cash. It would improve liquidity without creating another $2 million of revenue or gross profit at the collection date, because the sale has already been recorded. Conversely, recognizing additional sales on credit could improve reported revenue while leaving near-term cash unchanged. These two examples explain why the next report should be assessed through both the income statement and the operating cash-flow reconciliation.

Inventory creates a related timing issue. The $6.151 million June balance represents products and components carried as assets, rather than spendable cash. Turning that balance into cash requires saleable equipment, deliveries and customer payment; the book value is not a guaranteed immediate liquidation value. Buying more inventory may be necessary to meet genuine orders, yet it can consume cash before those orders fund themselves. Cutting purchases can preserve cash while recreating the component constraints that affected the first quarter.

Purchase commitments should be evaluated within this production cycle. The $10.696 million disclosed amount concerns non-cancelable supplier orders due within a year, linked to sales forecasts and production requirements. Treating the entire amount as additional cash burn on top of a forecast already including production purchases would double count. Ignoring it because it is not bank debt would make the opposite mistake. The useful question is when supplier payments fall due relative to expected receipts and whether inventory and orders remain aligned. Commitments

The next-quarter evidence can support different conclusions. Lower receivables with stable sales and margin would support better cash conversion. Lower receivables accompanied by a sharp sales contraction might instead reflect less business. Higher inventory alongside documented delivery growth can be productive investment; higher inventory with weak shipments may require a closer look. None of those patterns can be settled by a single balance alone. This is especially relevant while the company is using outside capital to support both an existing device operation and an experimental drug program.

07 Notes, conditional capital and the limits of the shelf

The March 25, 2026 transaction included a $10 million convertible note carrying 8% interest, maturing on March 25, 2029 and initially convertible at $5.40 per ordinary share. Its June carrying value of approximately $4.432 million reflects accounting discounts and is not the face amount owed. Earlier short-term notes exchanged in the transaction are not additional current principal to add on top. Source

The March notes are secured by a lien on the company’s cash and contain covenants and default provisions. Lifeward reported compliance with all covenants at June 30, 2026. That dated statement is useful, but it does not eliminate the creditor’s security or establish perpetual compliance after later changes in the business. Liquidity needs to be assessed alongside those obligations. Source

The initial July financing added $5.580 million of notes at 8%, with a July 6, 2029 maturity and a $5.40 initial conversion price. Together, the March and initial July issuances represent $15.580 million of issued face principal before subsequent interest or changes. Conversion exchanges a debt claim for equity; it is not a second payment of the original proceeds to Lifeward. Source Source

Interest on the July notes is payable semiannually, with the first scheduled payment on December 31, 2026. The company can elect cash payment or addition to principal under the agreement. Capitalizing interest conserves immediate cash but increases the outstanding obligation. Default provisions include a higher interest rate and potential acceleration, so the contractual funding terms remain relevant even if management emphasizes the possibility of conversion. Source

The additional July tranche of $5.580 million is conditional. The agreement specifies qualifying ReWalk sales growth or a share-price condition of at least $13.80 for ten consecutive trading days, together with other closing requirements. It is not unrestricted cash available on demand, and a single price observation would not satisfy the sustained-price test. The capital plan should distinguish funds already received, conditional commitments and proceeds that would require investors to exercise warrants. Source

The prior ATM agreement expired in November 2025; the June 2026 report does not present it as an active source of first-half issuance. A $100 million shelf registration became effective in January 2026, but a shelf is issuance capacity, not cash. The smaller-public-float limitation restricts primary issuance under the relevant shelf rules. Separately, the August 3 resale registration covers 2,066,662 shares tied to the July notes and warrants and states that selling-shareholder resales produce no proceeds for Lifeward. Warrant exercises for cash are a separate event. Source Source

08 Dilution: ordinary shares, pre-funded securities and warrants

The September 25 proxy reports 2,832,016 ordinary shares outstanding on September 23, 2026. The June 30 balance sheet reported 2,828,362, compared with 1,524,431 at December 31, 2025 on the restated basis. Lifeward completed a one-for-twelve reverse split in February 2026, so comparisons with earlier unadjusted share counts or prices can be misleading. A reverse split changes the number and price per unit, not the economic amount of capital raised. Source Source

The March Oratech acquisition issued 1,250,363 ordinary shares and 1,006,113 pre-funded warrants. The pre-funded exercise price is $0.0001, meaning almost all the consideration is already accounted for before eventual exercise. Treating their exercise as a substantial future cash raise would be incorrect. These securities also differ from ordinary warrants with meaningful exercise prices, where exercise may deliver cash but remains conditional on investor behavior and contractual terms. Source

The March acquisition and financing included 3,148,147 ordinary warrants in aggregate, alongside the separate pre-funded warrants and convertible note. The initial July financing added notes and warrants covering 2,066,662 shares in total before interest. These are separate dated transaction exposures; older aggregate warrant tables should not be blindly added to them because that would count the same securities more than once. Source Source

The October 30 proposal is consequential because the relevant exchange cap is 565,389 shares. The proxy says that, without the approval, additional closings and covered conversion or exercise issuances cannot exceed the cap. Approval would remove that particular constraint. The proxy’s initial-July illustration alone would take shares to approximately 4.9 million and dilute existing holders’ proportional interest by approximately 42.2%, assuming the described conversion and exercise and excluding other securities. This is a scenario, not the current capitalization. Source

Authorized ordinary shares stood at 100 million at June 30, 2026. Authorization permits potential issuance; it is neither the current share count nor a prediction that the entire authorization will be used. The 2025 incentive plan has no automatic evergreen increase, according to the annual report. Options, restricted awards, pre-funded warrants and financing securities still create distinct paths to an expanded ordinary-share base. Source Source

What the vote changes for an existing holding

Using the September 23 ordinary-share count, adding the initial July exposure of 2,066,662 shares produces 4,898,678 shares. The added securities equal approximately 73.0% of the starting count, while the existing shares would retain approximately 57.8% of the enlarged total. The resulting 42.2% reduction in proportional ownership uses the post-issuance denominator. It is not the same percentage as the increase in the share count. The calculation excludes accrued interest and other securities and assumes the covered conversion and exercise occur. Proxy illustration

Removal of the exchange cap changes what can be issued under the covered arrangements; it does not convert those securities automatically. Note conversion generally replaces the relevant creditor claim with equity, whereas a warrant exercised for cash can bring new money into the company. A resale by an existing security holder transfers ownership between investors and does not by itself finance Lifeward. These distinct events can appear in the same financing narrative, but they should be tracked in separate lines when updating cash, debt and outstanding shares.

The proxy also describes beneficial-ownership limits. Those limits can affect how many shares a particular holder may own at a given moment, and they are distinct from the exchange cap being put to the vote. Approval of one constraint does not mean every other contractual condition disappears. A subsequent filing should therefore be checked for actual transactions and remaining obligations rather than assuming that all registered securities entered the public float on the meeting date.

09 The oral-insulin option and what the clinical evidence means

The Oratech acquisition closed on March 25, 2026 and added rights connected to the oral-insulin candidate ORMD-0801. The capsule approach aims to deliver insulin through the digestive system. For the equity story, the important distinction is between an acquired development opportunity and an approved treatment generating commercial revenue. The September presentation describes a Phase 2B program in development, rather than an achieved new clinical success. Source Source

The historical U.S. Phase 3 program failed its primary and secondary endpoints, as Oramed reported on January 11, 2023 and restated in its June 2023 quarterly report. Subsequent subgroup analysis generated a possible development hypothesis; it did not reverse the failed overall result. Fresh prospective evidence is needed to establish whether the revised approach produces a reproducible benefit. A favorable interpretation of selected past patients is not a successful new trial. Source

The June 2026 Lifeward accounts already include approximately $0.7 million of second-quarter oral-insulin clinical costs, encompassing services and amortization. Accordingly, the acquired cash and the development funding arrangements matter when judging the project. The program is not cost-free for Lifeward simply because a strategic presentation emphasizes financial support connected with the acquisition. Source

Evidence for rehabilitation devices is a different category. A 2016 systematic review pooled 14 studies and 111 patients using several powered exoskeletons, including ReWalk. About 76% walked without another person’s physical assistance after training while wearing the device. This was assisted-device walking, not recovery of unaided walking, and the pooled population was not a dedicated trial of ReWalk 7. The finding supports the functional premise while leaving product-specific outcomes, eligibility and reimbursement to their own evidence. Source

For a trader, the clinical distinction prevents two mistakes: valuing an experimental oral drug as an established product and interpreting a rehabilitation device as a cure for spinal cord injury. Commercial uptake and clinical utility can improve without making either claim. The next meaningful oral-insulin milestone is evidence that changes the probability of clinical success, supported by actual reported results rather than a distant market-size presentation.

10 Control, management and the small public float

Oramed held 1,250,363 ordinary shares, or 44.2% of Lifeward, at the September 23, 2026 ownership date in the proxy. The same disclosure excludes substantial additional pre-funded, warrant and note exposure because of beneficial-ownership limitations. That distinction matters: the ordinary stake measures current disclosed voting ownership, while the excluded instruments describe potential economic and capital exposure. Adding everything into one immediate voting percentage would misstate the position. Source

The management transition also links Lifeward and Oramed. The August 31 announcement makes Josh Hexter interim chief executive from September 1 while retaining a limited portion of his previous Oramed responsibilities. Mark Grant’s consultancy ran through September 30, 2026, so that scheduled transition period is already past. The October 1 filing then assigns Hexter the interim finance responsibilities until the planned November handover. The relevant governance test is delivery of the operating plan and clear treatment of related-party transactions during that transition. Source Source

Finviz data as of October 2, 2026 report approximately 1.50 million float shares, 6.99% short float and a short ratio of 11.34. The short settlement date is not stated, so these are dated third-party figures rather than an assertion about positions opened that day. The same data show 46.99% insider ownership and 1.14% institutional ownership; third-party categories and reporting dates differ from the proxy’s specific Oramed ownership measure. Source

With a small float and limited average turnover, relatively modest trading demand can produce difficult execution conditions. The short ratio uses a volume denominator and is not a countdown to forced covering. It does not establish a squeeze catalyst or offset the potential supply from financing securities. The dated reference close is $5.96 on October 1, 2026, from the data source’s daily series, separate from the ownership data. Source Source

Recent director filings also need correct labels. Haggai Zamir and Yonason Greenwald each reported an August 14, 2026 grant of 6,711 restricted share units at no purchase price. Those are compensation awards, not discretionary cash purchases of shares in the market. Their vesting conditions create incentives, but the filings do not show the directors spending personal cash to buy those units. Source Source

11 Red flags, the next report and the bottom line

The immediate red flags are a short cash cushion relative to historical consumption, substantial convertible and warrant exposure, concentrated receivables and execution during a management transition. The oral-insulin project adds clinical uncertainty to a business whose device sales already require working capital. The August 2026 going-concern disclosure ties those issues together: external funding remains part of the operating plan, not a remote contingency. Source

For the October 30 vote, the first item to watch is the actual result and the precise securities covered by the approval. Afterward, distinguish removal of an issuance cap from completed conversion, completed warrant exercise or a new tranche closing. Each produces a different combination of debt reduction, cash inflow and share issuance. The shareholder impact depends on that combination, not merely on whether a corporate announcement calls financing successful. Source Source

For the next financial report, follow whether AlterG and ReWalk sustain deliveries, whether gross profit keeps pace with sales, whether receivables turn into cash and whether operating burn declines. A stronger revenue number coupled with larger receivables and unchanged consumption would be a weaker result than the growth headline suggests. Conversely, a smaller operating deficit and improved collections would directly address the concern that each recovery quarter still needs another capital transaction.

Lifeward’s bottom line is a financing-sensitive commercial recovery with an additional experimental-drug option. The second-quarter rebound gives the operating thesis something measurable to build on. The October shareholder vote, the debt terms and the difference between current ordinary shares and potential issuance define what existing shareholders may retain of that progress. Durable improvement requires evidence in cash and gross profit as well as in sales; the distant product roadmap remains conditional until those milestones are actually delivered. Source Source Source